Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell

Area of Science:

• Immunology
• Cell Therapy
• Cancer Research

Background:

• Adoptive cell transfer of antitumor lymphocytes shows promise for long-term immunity.
• Generating potent cytotoxic T lymphocytes (CTL) consistently and rapidly for patients remains a challenge.
• Existing methods are hampered by in vivo immunoregulation, limiting therapeutic efficacy.

Purpose of the Study:

• To establish a clinical-grade culture system for reproducible generation of antigen-specific CTL.
• To overcome limitations in current adoptive cell therapy protocols.
• To develop a reliable method for producing therapeutic antitumor lymphocytes.

Main Methods:

• Created a standardized, renewable artificial antigen-presenting cell (aAPC) line co-expressing key immune molecules (HLA class I, CD54, CD58, CD80, CD83).
• Tested aAPC for their ability to generate tumor antigen-specific CTL under optimized conditions.
• Assessed CTL quantity, phenotype, effector function, and in vitro longevity.

Main Results:

• aAPC efficiently generated large numbers of functional CTL recognizing diverse tumor antigens.
• Generated CTL exhibited a phenotype indicative of in vivo persistence and survived long-term ex vivo.
• Clinical-grade aAPC(33) rapidly produced sufficient CTL numbers from all melanoma patients tested.
• CTL specifically lysed melanoma tumor lines expressing target antigens.

Conclusions:

• Clinical-grade aAPC(33) provides a robust platform for generating antitumor CTL.
• This system is ready for clinical translation in adoptive cell transfer therapies.
• Enables reproducible and timely production of therapeutic CTL for cancer patients.